Prenumeration
With a new THC/CBD medical cannabis oil approved, which is ready for sales under the Danish pilot program, STENOCARE A/S (“STENOCARE” or the “Company”) has regained the position as the only provider of all three essential oil products under the program; a THC oil, CBD oil, and the new THC/CBD oil. The last time STENOCARE had all three products approved in Denmark back in 2018/2019, the Company reported net sales of DKK 4.3m in Q1-19 with a positive net result. STENOCARE are now back in the same situation in Denmark, and with products approved in five additional markets. With estimated net sales of DKK 66.6m by 2026, and with an applied P/S multiple of 4.5x, a potential present value per share of DKK 8.8 (8.8) is derived in a Base scenario.
Read the equity research report here
About Analyst Group: One of Sweden's leading analysis houses with a focus on small and medium-sized listed companies.
Read more about Analyst Group
This is a press release from Analyst Group regarding the publication of an equity research report on STENOCARE. Readers may assume that Analyst Group has received compensation for making the equity research report. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation, or anything else that could be considered a subjective assessment.